Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$12.04 USD
+0.04 (0.33%)
Updated May 24, 2024 04:00 PM ET
After-Market: $12.05 +0.01 (0.08%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Verona Pharma PLC American Depositary Share [VRNA]
Reports for Purchase
Showing records 161 - 180 ( 189 total )
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Q4/FY18 Financials; Data Rich 2019; Interim DPI/COPD Results in March
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Selloff on Exploratory RPL554 Phase 2 Data Overdone; Next Catalyst Rich 2019
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
R-D Day Highlights RPL554 First- and Best-in Class Profile in Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Verona Pharma PLC American Depositary Share
Industry: Medical - Biomedical and Genetics
ERS Oral Late Breaker Strengthens RPL554 Clinical Profile for COPD In Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
Q1 Financials; RPL554 Clinical Development On-Track
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
Nebulized RPL554: Significant, Meaningful Ph2b for COPD Maintenance
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
RPL554 Improves Lung Function in CF after only a Single Dose
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
Top-line Data Readout for RPL554 in COPD and CF Trials Ahead of Schedule Again
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
2018 Outlook: First Clinical CF Results and More from the COPD Program
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
Cash Runway into 2019 Covers Potential 2018 Clinical Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Verona Pharma PLC American Depositary Share
Industry: Unclassified
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D